



One place for your practice and patients— every step of the way

myAgios® Patient Support Services assists your patients with thalassemia by providing personalized education and customized treatment support through a single point of engagement.

Treatment
Support

Access and
Assistance

Patient
Education

Prescription Support

Scan to download the AQVESME™ Start Form

Find more help at 1-877-77-AGIOS (1-877-772-4467).

Agios Clinical Educators (ACEs) and Patient Support Managers (PSMs) do not provide medical advice. For medical advice or treatment-related questions, patients are instructed to talk to their healthcare team.

INDICATION

AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: HEPATOCELLULAR INJURY

AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected.

Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS.

WARNINGS AND PRECAUTIONS

Hepatocellular Injury

AQVESME can cause hepatocellular injury. Avoid use of AQVESME in patients with cirrhosis. In patients with thalassemia treated with AQVESME, liver injury with and without jaundice has been observed within the first 6 months of exposure. Obtain liver tests

Please see additional Important Safety Information throughout and full Prescribing Information for AQVESME, including Boxed Warning.



Your patients have a dedicated team at myAgios® Patient Support Services

Agios Clinical Educators (ACEs) and Patient Support Managers (PSMs) are here to help guide your patients living with thalassemia along every step of their journey.



What's an ACE?

An ACE is there from the start to offer personalized guidance to people living with thalassemia with or without a prescription.

ACEs help your patients:

- Get introduced to the PSM to learn more about their health insurance options
- Learn about their disease
- Set goals for living with their condition and discuss treatment and monitoring considerations
- Connect with other patients and hear from experts on webinars



What's a PSM?

A PSM helps people prescribed AQVESME™ (mitapivat) get access to and stay on AQVESME.

PSMs help your patients:

- Connect to ACEs to learn about their condition and treatment considerations
- Understand financial assistance and any eligibility criteria
- Get their AQVESME prescription filled
- Provide support through ongoing adherence

PSMs help you and your office:

- Navigate the patient's insurance coverage
- Address prior authorization requirements and appeals
- Coordinate all fulfillment and delivery with the exclusive Specialty Pharmacy

The myAgios team can connect with your patients in their preferred language, including Chinese, Arabic, Vietnamese, and others.

ACEs and PSMs do not provide medical advice. For medical advice or treatment-related questions, patients are instructed to talk to their healthcare team.

IMPORTANT SAFETY INFORMATION (cont.)

(including ALT, AST, alkaline phosphatase, total bilirubin with fractionation) prior to the initiation of AQVESME, then every 4 weeks for the first 24 weeks, and as clinically indicated thereafter. Interrupt AQVESME if clinically significant increases in liver tests are observed or alanine aminotransferase is >5 times the upper limit of normal (ULN). Complete a comprehensive evaluation to rule out other causes of liver injury when drug-induced liver injury is suspected. Discontinue AQVESME if hepatocellular injury due to AQVESME is suspected.

Symptoms and signs of early liver injury may mimic those of thalassemia. Advise patients to report new or worsening symptoms of loss of appetite, nausea, right-upper-quadrant abdominal pain, vomiting, scleral icterus, jaundice, or dark urine while on AQVESME treatment.

During the double-blind period, 2 of 301 patients (0.66%) with thalassemia treated with AQVESME experienced adverse reactions suggestive of hepatocellular injury. Three additional patients experienced adverse reactions suggestive of hepatocellular injury during the open-label extension periods after switching from placebo to AQVESME. Of these 5 patients, 2 had serious liver injury requiring hospitalization, including 1 patient who developed jaundice (peak bilirubin 32 mg/dL). Another patient developed jaundice (peak bilirubin 4 mg/dL).

Please see additional Important Safety Information throughout and full Prescribing Information for AQVESME, including Boxed Warning.



All-in-one enrollment and support for your patients

myAgios® Patient Support Services offers a single point of engagement for your office staff when seeking care for your patients living with thalassemia. AQVESME™ (mitapivat) has a Risk Evaluation and Mitigation Strategy (REMS) to help ensure safe use, regulatory compliance, and coordinated care for patients.



1 Personalized Patient Education

At diagnosis or when the patient wants to learn more, our **ACEs** provide education and support



2 Prescription Support

To prescribe AQVESME, there are 2 forms to complete with your patients:

- REMS Patient Enrollment Form
- AQVESME Start Form to enroll your patients in myAgios Patient Support Services

Start Form



3 Access and Assistance

PSMs work directly with your patients and your practice to discuss AQVESME and how to navigate insurance hurdles and coordinate delivery through the exclusive Specialty Pharmacy



4 Customized Treatment Support and Adherence

Patients can get help to prepare for appointments and get questions about AQVESME answered via text or call with their **ACEs** or **PSMs**



myAgios can help patients determine their eligibility for programs to help them access AQVESME

AQVESME Copay Program	\$0 responsibility for commercially insured patients, regardless of how much they make
Patient Assistance Program	Free prescriptions for eligible patients who are uninsured or who do not have coverage for AQVESME
Coverage Interruption Program	Free prescriptions for eligible patients experiencing an interruption in their insurance coverage. Patients with government health insurance plans are not eligible.

Full terms and conditions are available at myagios.com/AQVESME.

Find information on financial assistance by visiting myagios.com/AQVESME.

IMPORTANT SAFETY INFORMATION (cont.)

without requiring hospitalization. These reactions were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of $>5 \times \text{ULN}$ with or without jaundice. All patients discontinued treatment with AQVESME, and these reactions improved upon treatment discontinuation.

AQVESME REMS

AQVESME is available only through a restricted program under a REMS called the AQVESME REMS because of the risk of hepatocellular injury.

Please see additional Important Safety Information throughout and full Prescribing Information for AQVESME, including Boxed Warning.




Start AQVESME™ in 3 simple steps

Once you and your patient have reviewed AQVESME clinical and REMS information and decided AQVESME is right for them, these are the steps to start treatment promptly:

- 1 Complete the AQVESME Start Form and your one-time HCP AQVESME REMS certification**
After you and your patient sign and submit the AQVESME Start Form, the patient will be enrolled in myAgios® Patient Support Services. The myAgios team can assist you and your patient in determining insurance coverage and exploring financial assistance options.
- 2 Ensure your patient's pre-treatment liver test is completed**
The pre-treatment liver test (blood test) must be completed within 4 weeks of the first prescription being filled. The myAgios team will work with you and your patient to determine the ideal timing to complete the required pre-treatment liver test based on the status of insurance determination.
- 3 Enroll your patient in AQVESME REMS**
To enroll, you and your patient must complete and sign the AQVESME REMS Patient Enrollment Form, including documentation of the patient's pre-treatment liver test and confirmation that the patient is appropriate for AQVESME.

Patient monitoring requirements include a pre-treatment liver test before initiating therapy and monitoring liver function every 4 weeks during the first 24 weeks of treatment and as clinically indicated thereafter



*AQVESME is one pill taken twice daily, supplied as a 28-day pack.

The myAgios team will help ensure AQVESME is delivered directly to your patient's home through an exclusive REMS-certified Specialty Pharmacy.

For any questions regarding REMS, visit www.AQVESMEREMS.com or call **1-800-625-9951**

For any questions regarding myAgios, visit myAgios.com or call **1-877-77-AGIOS (1-877-772-4467)**.



Prescribe AQVESME and see more resources for your patients and practice.

Scan the QR code or visit myagios.com/aqvesme/hcp.



IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$) among patients taking AQVESME were headache and insomnia.

DRUG INTERACTIONS

- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
- Moderate CYP3A Inhibitors: Avoid concomitant use.
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, see full Prescribing Information for recommended dosage for drug interactions with moderate CYP3A inducers.

- Sensitive CYP3A Substrates, including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
- CYP2B6, CYP2C, and UGT1A1 Substrates: Monitor patients for efficacy of the substrates with narrow therapeutic index.
- P-gp Substrates: Monitor patients for adverse reactions of the substrates with narrow therapeutic index.

HEPATIC IMPAIRMENT

Avoid use of AQVESME in patients with cirrhosis (Child-Pugh Class A, B, or C).

Please see full Prescribing Information for AQVESME, including Boxed Warning.